Evidence map›Paper›PMID 38802071›Full record

ArticleAutophagy2024

Development and characterization of phospho-ubiquitin antibodies to monitor PINK1-PRKN signaling in cells and tissue.

Jens O Watzlawik, Xu Hou, Tyrique Richardson, Szymon L Lewicki, Joanna Siuda, Zbigniew K Wszolek, Casey N Cook, Leonard Petrucelli, Michael DeTure, Dennis W Dickson and 8 more

Abstract read
In one paragraph

Article in Autophagy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Species-dependent activities of the PINK1-parkin axis.Translational neurodegeneration · 2026
    Review
  2. Article
  3. Frontiers in aging neuroscience · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. PTEN: a new dawn in Parkinson's disease treatment.Frontiers in cellular neuroscience · 2025
    Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Jens O WatzlawikDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0003-0610-0267
Xu HouDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0003-3011-4378
Tyrique RichardsonDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Szymon L LewickiDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Joanna SiudaDepartment of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland.
Zbigniew K WszolekDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Casey N CookDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Leonard PetrucelliDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Michael DeTureDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Odetta AnticoMRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK.
Miratul M K MuqitMRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK.
Jordan B Fishman21st Century Biochemicals Inc, Marlborough, MA, USA.
Karima PiraniImmunoPrecise Antibodies Ltd, Victoria, BC, Canada.
Ravindran KumaranAbcam plc, Cambridge, UK.
Nicole K PolinskiThe Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Fabienne C FieselDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-1919-9676
Wolfdieter SpringerDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-1178-3149

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI ADAM L. BOXER · 2019 to 2026
$120.9M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$33.5M
Utilization of proteomics and lipidomics to identify modifiers of LBDU54NS110435 · NINDS · MAYO CLINIC JACKSONVILLE · PI MCLEAN, PAMELA J · 2019 to 2023
$14.5M
Molecular mechanisms of PINK1-PRKN directed mitochondrial quality controlRF1NS085070 · NINDS · MAYO CLINIC JACKSONVILLE · PI SPRINGER, WOLFDIETER · 2019 to 2019
$2.8M
Mitochondrial Sirtuin 3 in Parkinson's diseaseR01NS110085 · NINDS · MAYO CLINIC JACKSONVILLE · PI MCLEAN, PAMELA J, SPRINGER, WOLFDIETER · 2019 to 2023
$2.5M
Selective autophagy in Alzheimer's disease and related dementiasR56AG062556 · NIA · MAYO CLINIC JACKSONVILLE · PI FRYER, JOHN DAVID, SPRINGER, WOLFDIETER · 2019 to 2019
$782k
NIA NIH HHS P30 AG062677NIA NIH HHS R56 AG062556NIA NIH HHS U19 AG063911NINDS NIH HHS R01 NS110085NINDS NIH HHS RF1 NS085070NINDS NIH HHS U54 NS110435Wellcome Trust
6 · The paper itself

Abstract

The selective removal of dysfunctional mitochondria, a process termed mitophagy, is critical for cellular health and impairments have been linked to aging, Parkinson disease, and other neurodegenerative conditions. A central mitophagy pathway is orchestrated by the ubiquitin (Ub) kinase PINK1 together with the E3 Ub ligase PRKN/Parkin. The decoration of damaged mitochondrial domains with phosphorylated Ub (p-S65-Ub) mediates their elimination though the autophagy system. As such p-S65-Ub has emerged as a highly specific and quantitative marker of mitochondrial damage with significant disease relevance. Existing p-S65-Ub antibodies have been successfully employed as research tools in a range of applications including western blot, immunocytochemistry, immunohistochemistry, and enzyme-linked immunosorbent assay. However, physiological levels of p-S65-Ub in the absence of exogenous stress are very low, therefore difficult to detect and require reliable and ultrasensitive methods. Here we generated and characterized a collection of novel recombinant, rabbit monoclonal p-S65-Ub antibodies with high specificity and affinity in certain applications that allow the field to better understand the molecular mechanisms and disease relevance of PINK1-PRKN signaling. These antibodies may also serve as novel diagnostic or prognostic tools to monitor mitochondrial damage in various clinical and pathological specimens.

Indexed as

Protein KinasesSignal TransductionUbiquitinUbiquitin-Protein LigasesAnimalsAntibodiesAntibodies, MonoclonalHEK293 CellsHumansMiceMitochondriaMitophagyPhosphorylationPTEN-Induced Putative KinaseRabbitsAntibodiesAntibodies, Monoclonalparkin proteinProtein KinasesPTEN-Induced Putative KinaseUbiquitinUbiquitin-Protein LigasesAutophagymitochondriamitophagyParkinson diseasePINK1ubiquitin

Identifiers

PMID38802071
PMCPMC11346534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.